Article
Altered epitopes enhance macrophage-mediated anti-tumour immunity to low-immunogenic tumour mutations.
Immunology - 1 Dec 2024
Yu Qiumin, Zhang Tingran, He Tiandi, Yang Yifan, Zhang Wanli, Kang Yanliang, Wu Zijie, Xie Wenbin, Zheng Jiaxue, Qian Qianqian, Li Guozhi, Zhang Di, Mao Qiuli, Gao Zheng, Wang Xiaoning, Shi Xupeiyao, Huang Shitong, Guo Hanlin, Zhang Haoyu, Chen Lingxiao, Li Ximing, Deng Danni, Zhang Li, Tong Yue, Yao Wenbing, Gao Xiangdong, Tian Hong
Abstract excerpt
Personalized neoantigen therapy has shown long-term and stable efficacy in specific patient populations. However, not all patients have sufficient levels of neoantigens for treatment. Although somatic mutations are commonly found in tumours, a significant portion of these mutations do not trigger an immune response. Patients with low mutation burdens continue to exhibit unresponsiveness to this treatment. We...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.